Michael Rosenblum, MD, PhD
Basic profileDermatology
Michael Rosenblum is a Dermatology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Autologous Polyclonal Tregs for Lupus
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202519 payments$29,512
- GENZYME CORPORATIONProgram year20251 payment$3,548
- Eli Lilly and CompanyProgram year20251 payment$800
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
39%Corticosteroid39%Prednisone100%Part D≥11 patientsCancer & immunology
16.9%Folate Analog Metabolic Inhibitor16.9%Methotrexate100%Part D<11 patientsDermatology
13.6%Corticosteroid13.6%Triamcinolone Acetonide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 2012–2025 per NIH RePORTER. The latest:
- Restoring Immune Balance in Hiddradenitis Suppurativa
University of California, San Francisco
FY2024$687,733R01AR075864 - Elucidating the Role of Regulatory T cells in Establishing and Maintaining a Th2 Niche in Skin
University of California, San Francisco
FY2024$682,917R01AR077553
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Bridget Grant, MD
Bassett Medical Center
Robert Modlin, MD
University of California, Los Angeles
Andrew Blauvelt, MD
University of Maryland School of Medicine
Howard Maibach, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”